



Aravax Appoints Dr Adrian Parry as Director of CMC as it Continues to Build Phase 3 Development Capabilities

Melbourne, Australia and Oxford, UK– 23 June 2025, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Dr Adrian Parry as Director of CMC (Chemistry, Manufacturing and Controls), based at the Company's Oxford, UK site.

Adrian is hugely experienced in the field with more than 20 years of development expertise including the delivery of multiple, complex GMP drug products. He has significant experience overseeing outsourced CMC activities as well as designing and developing CMC strategies to support regulatory approvals following multiple interactions with the relevant Competent Authorities.

Adrian joins Aravax from Scancell where he has been Head of Manufacturing since 2019, overseeing GMP manufacturing activities from drug substance to packaged IMP as well as compiling CMC regulatory submissions. Prior to working at Scancell, he was Head of Small Molecule CMC at Mereo BioPharma, managing outsourced GMP manufacturing activities. Adrian was previously New Product Development Director at Juniper Pharmaceuticals and has held further CMC positions at Circassia, Shire Pharmaceuticals, Prosidion, Evotec and OSI Pharmaceuticals. Adrian holds a PhD in Physical Organic/Analytical Chemistry from The Open University, following an MSc in Advanced Analytical Chemistry from the University of Bristol.

Dr Adrian Parry Director of CMC at Aravax said, “Food allergy is a rapidly growing problem around the world and places a significant burden on patients and their families. I am excited about Aravax’s focus on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies, and to have the opportunity to apply my experience towards reaching that goal.”

Dr Pascal Hickey, CEO of Aravax, said, “Adrian is hugely experienced and his appointment is another significant step in the growth of our international team as we continue to build our capabilities ahead of the read out of our Phase II clinical trial. We very much look forward to working with him.”

ENDS

About Aravax

Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches. Aravax’s proprietary platform generates engineered peptides that precisely retrain the immune system and restore the body’s ability to safely tolerate food allergens, without putting patients at risk of treatment-induced acute allergic reactions, including anaphylaxis. The lead product, PVX108, is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. Aravax is also developing a pipeline of products tackling additional significant food allergy indications.

Aravax is an international company headquartered in Melbourne, Australia with a subsidiary in Oxford, UK and operations in USA and Europe. Aravax’s investors include leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper.

For more information visit: www.aravax.com.au

For further information please contact

Media – Australia

Kirrily Davis, E: kdavis@bcpvc.com M: +61 (0)401 220228

Media - International

Sue Charles, Charles Consultants E: sue.charles@charles-consultants.com M: +44 (0)7968 726585

Chris Gardner, E: Chris@CGComms.onmicrosoft.com M: +44 (0)7956 031077